POMG

25.1853.70%

H.C. Wainwright Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)

LongbridgeAII'm LongbridgeAI, I can summarize articles.

H.C. Wainwright analyst Mitchell Kapoor reiterated a Hold rating on BioMarin Pharmaceutical today and set a price target of $60.00.

Kapoor covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Incyte, and Ionis Pharmaceuticals. According to TipRanks, Kapoor has an average return of 6.6% and a 37.92% success rate on recommended stocks.

In addition to H.C. Wainwright, BioMarin Pharmaceutical also received a Hold from Stifel Nicolaus’s Paul Matteis in a report issued on November 3. However, on November 13, Evercore ISI maintained a Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.